Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis.
Gerald F Watts, Christie M Ballantyne, Agustin Blanco Echevarria et al.
✦ AI-curated · Sources linked
In 30 seconds
Two double-blind, placebo-controlled randomized trials evaluated plozasiran in 757 adults with severe hypertriglyceridemia. Participants received plozasiran or placebo, with pooled analyses assessing adjudicated acute pancreatitis. At month 12, placebo-adjusted median triglyceride changes were −45 and −47 percentage points in the two trials. In the pooled analysis, acute pancreatitis rates were 1 per 100 patient-years with plozasiran and 5 per 100 patient-years with placebo (rate ratio, 0.22; P = 0.008). Adverse events during treatment occurred in 73% of each pooled group.
Key findings
- At month 12, placebo-adjusted median triglyceride changes were −45 percentage points (95% CI, −51 to −38) and −47 percentage points (95% CI, −54 to −39) in the two trials.
- Triglyceride levels below 500 mg per deciliter at 12 months occurred in 91% and 93% of plozasiran recipients versus 51% and 50% of placebo recipients (P<0.001).
- Acute pancreatitis rates were 1 per 100 patient-years with plozasiran and 5 per 100 patient-years with placebo (rate ratio, 0.22; P = 0.008).
- Treatment-emergent adverse events occurred in 73% of patients in both pooled groups.
Why it matters
Severe hypertriglyceridemia is associated with acute pancreatitis, and these trials found that plozasiran lowered triglyceride levels while the pooled analysis showed fewer pancreatitis events than with placebo. The findings provide clinical outcome evidence alongside lipid changes, although the reported pancreatitis rates and follow-up are specific to the trial setting.
What to keep in mind
The abstract reports pancreatitis outcomes from a pooled analysis and follow-up to 12 months; it does not provide longer-term outcome data.